Aratana Therapeutics (PETX) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aratana Therapeutics Reports Third Quarter 2015 Results
November 5, 2015 5:01 PM ESTKANSAS CITY, Kan., Nov. 5, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its third quarter 2015 financial and operational results. For the quarter ended September 30, 2015, Aratana reported a net loss of $54.4 million or $1.58 basic loss per share. Results included a non-cash asset impairment charge of $43.4 million or $1.26 per share.
"Our portfolio of pet therapeutics continues to move through the regulatory process and if successful, we expect to bring an unprecedented number of innovative... More
